HCID 66594381, compound → HCID 76182080, compound
Reaction equation
Cl.N[C@H]1CCCC[C@H]1CNCCO.[F:14][C:15]1[CH:20]=[C:19]([F:21])[CH:18]=[CH:17][C:16]=1[CH2:22][NH:23][C:24]([C:26]1[C:27](=[O:56])[C:28]([O:48]CC2C=CC=CC=2)=[C:29]2[C:45](=[O:46])[N:33]3[CH:34]4[CH:39]([CH2:40][N:41]([CH2:42][CH2:43][OH:44])[CH:32]3[CH2:31][N:30]2[CH:47]=1)[CH2:38][CH2:37][CH2:36][CH2:35]4)=[O:25]>>[F:14][C:15]1[CH:20]=[C:19]([F:21])[CH:18]=[CH:17][C:16]=1[CH2:22][NH:23][C:24]([C:26]1[C:27](=[O:56])[C:28]([OH:48])=[C:29]2[C:45](=[O:46])[N:33]3[CH:34]4[CH:39]([CH2:40][N:41]([CH2:42][CH2:43][OH:44])[CH:32]3[CH2:31][N:30]2[CH:47]=1)[CH2:38][CH2:37][CH2:36][CH2:35]4)=[O:25]Participants
Procedure
In a manner similar to that described in example Z-35, from 16a (45 mg, 0.0957 mmol) and racemic-2-({[(1S,2S)-2-aminocyclohexyl]methyl}amino)ethanol hydrochloride (102 mg, 0.418 mmol) was prepared racemic-(4aS,6aS,14aS)-N-[(2,4-difluorophenyl)methyl]-6-(2-hydroxyethyl)-11,13-dioxo-12-[(phenylmethyl)oxy]-1,2,8,4,4a,5,6,6a,7,11,13,14a-dodecahydropyrido[1′,2′:4,5]pyrazino[1,2-a]quinazoline-10-carboxamide (7 mg, 12%) as a white solid after silica gel chromatography (1.12% methanol/dichloromethane gradient elution). This material was deprotected in a second step similar to the procedure described in example Z-37. Thus, from racemic-(4aS,6aS,14aS)-N-[(2,4-difluorophenyl)methyl]-6-(2-hydroxyethy)-11,13-dioxo-12-[(phenylmethyl)oxy]-1,2,3,4,4a,5,8,8a,7,11,13,14a-dodecahydropyrido[1′,2′:4,5]pyrazino[1,2-a]quinazoline-10-carboxamide (7 mg, 0.0118 mmol) the title compound was prepared after purification by HPLC (3 mg, 50%). 1H NMR (CDCl3) 12.57 (br s, 1H), 10.45 (m, 1H), 8.29 (s, 1H), 7.34 (m, 1H), 6.78 (m, 2H), 4.80 (m, 1H), 4.71 (s, 1H), 4.62 (m, 2H), 4.44 (m, 1H), 4.33 (m, 1H), 3.75 (m, 1H), 3.62-3.20 (m, 3H), 3.13 (m, 1H), 2.74-2.71 (m, 2H), 2.24 (m, 1H), 1.90-137 (m, 12H), 1.27-1.23 (m, 3H) 1.12 (m, 1H); ES+MS: 503 (M+1).
Workup
- washafter silica gel chromatography (1.12% methanol/dichloromethane gradient elution)
- customafter purification by HPLC (3 mg, 50%)
Sources & evidence
- ORD record
- ord-bcce129a82634fd6867a339d2affd7e7
- Source dataset
- uspto-grants-2016_03
- Patent number
- US09273065B2
Reaction notes
Loading…